10x Genomics Technology Supports TenK10K Project Led by Garvan Institute of Medical Research to Help Transform the Treatment of Complex Diseases

Rhea-AI Summary

10x Genomics (Nasdaq: TXG) is supporting the TenK10K project, a large-scale study led by the Garvan Institute of Medical Research. The project aims to map 50 million human cells from 10,000 people to identify unique genomic fingerprints of autoimmune diseases, heart diseases, and cancer. The Garvan Institute has selected 10x Genomics' Chromium GEM-X products for single cell data generation, which offers increased sensitivity, throughput, data quality, and sample recovery.

The TenK10K project builds on the success of the Garvan Institute's OneK1K study and aims to develop commercial tests for various autoimmune diseases, early trials of RNA therapies, and potential treatments for cancers and long COVID. This collaboration showcases the potential of single cell analysis at a massive scale to impact disease understanding, diagnosis, treatment, and cure.

Positive

• Involvement in a large-scale, multi-year study (TenK10K) led by a prestigious research institute
• Selection of 10x Genomics' Chromium GEM-X products for the project, demonstrating product superiority
• Potential for increased adoption and sales of Chromium GEM-X products in translational research
• Expansion of 10x Genomics' presence in the growing field of personalized medicine

Negative

• None.

Medical Research Analyst

The TenK10K project represents a significant leap forward in personalized medicine. By mapping 50 million cells from 10,000 individuals, this study aims to uncover unique genomic fingerprints for various complex diseases. The use of 10x Genomics' Chromium GEM-X technology for single-cell sequencing is crucial, as it offers increased sensitivity, throughput and data quality.

This project could lead to more accurate disease prediction and tailored treatments for autoimmune diseases, heart conditions and cancers. The potential development of commercial tests and early trials of RNA therapies could revolutionize patient care. However, it's important to note that translating these findings into clinical applications may take considerable time and further validation.

Financial Analyst

This collaboration with the Garvan Institute positions 10x Genomics (NASDAQ: TXG) at the forefront of a groundbreaking research project. The selection of Chromium GEM-X products for this large-scale study validates the company's technology and could lead to increased adoption in the research community. While the immediate financial impact may be , the long-term potential is significant.

If successful, this project could drive demand for 10x Genomics' products in both research and clinical settings. The company's involvement in developing tools for personalized medicine aligns with growing market trends. However, investors should be aware that the timeline for potential commercial applications is likely extended and success is not guaranteed in this complex field.

Biotech Industry Expert

The TenK10K project highlights the growing importance of single-cell analysis in biomedical research. 10x Genomics' involvement demonstrates the company's strong position in this field. The project's scale - 10 times larger than the previous OneK1K study - could provide unprecedented insights into disease mechanisms.

The potential development of commercial tests and therapies based on this research could open new revenue streams for companies in the precision medicine space. However, it's important to remember that the path from research to marketable products is often long and uncertain. The collaboration with Illumina also underscores the importance of partnerships in advancing complex scientific endeavors. This project could set a new standard for large-scale genomic studies, potentially influencing future research directions and funding allocations in the biotech industry.

Garvan Institute's TenK10K Project Aims to Map 50 Million Human Cells from 10,000 People

PLEASANTON, Calif., Aug. 5, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today its involvement in TenK10K, a large-scale, multi-year study led by the Garvan Institute of Medical Research. The TenK10K project intends to map 50 million human cells from 10,000 people to identify unique genomic fingerprints of autoimmune diseases, heart diseases and cancer. For this groundbreaking project, the Garvan Institute selected Chromium GEM-X products to generate single cell data to improve the accuracy of predicting disease risk and treatment response.

"TenK10K has the potential to enable a significant step forward in personalized medicine," said Professor Joseph Powell, leader of the TenK10K project, Program Director for Translational Genomics at the Garvan Institute of Medical Research, and Director of the UNSW Cellular Genomics Futures Institute. "Through single cell sequencing, which analyzes individual cells rather than an average of many cells, we can see fingerprints that we've never been able to distinguish. We are excited by translational opportunities that come from combining these leading sequencing and single cell technologies with advanced machine learning methods."

One of the largest projects of its kind, TenK10K aims to improve how accurately disease-linked immune cell fingerprints can be identified and develop:

• Commercial tests to identify the right therapy for challenging autoimmune diseases including multiple sclerosis, rheumatoid arthritis, lupus, type 1 diabetes, spondylitis, inflammatory bowel disease and Crohn's disease
• Early trials of powerful new RNA therapies
• Potential early targets for treatments for cancers and long COVID
• Tests to track the aftermath of heart attacks and identify risk of sudden death

As part of this new study, the Garvan Institute will use Chromium GEM-X products, the next generation of 10x Genomics' leading single cell technology, delivering increased sensitivity, throughput, data quality and sample recovery. GEM-X is uniquely positioned for translational research, delivering class-leading performance at larger scale and lower cost, even with more challenging samples.

"Single cell analysis at a massive scale has the potential to make a massive impact on how we understand, diagnose, treat and ultimately cure disease. We are thrilled to see the Garvan Institute help turn this potential into reality and use our new Chromium GEM-X technology as part of their groundbreaking TenK10K project," said Ben Hindson, Co-Founder and Chief Scientific Officer at 10x Genomics. "Enabling more researchers to harness the full power of high-performance single cell analysis at larger scale and lower cost is what drives our continued velocity of innovation."

TenK10K builds on the early success of the Garvan Institute's OneK1K pioneering study. For a 2022 paper published in Science, Powell and a team of researchers used single cell sequencing technologies from 10x Genomics to analyze the genomic profile of more than one million cells from 1,000 people. This study led to a proof-of-principle clinical trial at 10 hospitals in Sydney, Australia to help match individual patients with the most effective treatment.

"The early results suggest we can predict a patient's response to a therapy based on their genetic profile," Powell added.

For the TenK10K project, the Garvan Institute has partnered with Illumina, which is providing supplies, equipment and specialist research support to the Garvan Institute.

About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the "safe harbor" provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s products, performance, configuration, capabilities, usage and anticipated projects utilizing 10x Genomics technologies. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. Other risks and uncertainties that could affect 10x Genomics' financial and operating results and cause actual results to differ materially from those suggested by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the "SEC") from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance, usage and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics' views as of any date subsequent to the date of this press release.

Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-technology-supports-tenk10k-project-led-by-garvan-institute-of-medical-research-to-help-transform-the-treatment-of-complex-diseases-302214699.html

SOURCE 10x Genomics, Inc.

FAQ

What is the TenK10K project and how is 10x Genomics (TXG) involved?

The TenK10K project is a large-scale study led by the Garvan Institute of Medical Research, aiming to map 50 million human cells from 10,000 people. 10x Genomics (TXG) is involved by providing their Chromium GEM-X products for single cell data generation in the project.

What are the potential applications of the TenK10K project using 10x Genomics (TXG) technology?

The TenK10K project aims to develop commercial tests for autoimmune diseases, early trials of RNA therapies, potential treatments for cancers and long COVID, and tests to track heart attack aftermath and identify sudden death risk, using 10x Genomics (TXG) single cell sequencing technology.

How does the Chromium GEM-X technology from 10x Genomics (TXG) benefit the TenK10K project?

10x Genomics' (TXG) Chromium GEM-X technology offers increased sensitivity, throughput, data quality, and sample recovery. It is uniquely positioned for translational research, delivering class-leading performance at larger scale and lower cost, even with challenging samples.

What was the outcome of the Garvan Institute's OneK1K study that used 10x Genomics (TXG) technology?

The OneK1K study, which used 10x Genomics (TXG) single cell sequencing technologies, analyzed over one million cells from 1,000 people. It led to a proof-of-principle clinical trial at 10 hospitals in Sydney, Australia, to help match individual patients with the most effective treatment based on their genetic profile.